Intriguingly, Ang II led to greater hypertrophic changes in ApoEKO mice than wild-type (WT) mice, 22 indicating a critical role of ApoE deficiency in Ang II-mediated hypertrophic effects in hearts. However, the interaction between the apelin/ apelin receptor and Ang II-Ang II type 1 receptor signaling in heart disease and ApoE-null status is poorly defined. In the present study, we hypothesized that apelin is a negative regulator of Ang II-mediated myocardial remodeling, fibrosis, and injury. We evaluated the effects of apelin deficiency on aging-mediated and Ang II-mediated heart disease and the protective role of pyr1-apelin-13 in the atherosclerosis-prone ApoEKO mice. We showed that the pyr1-apelin-13 peptide pathway is a key protective mechanism against heart disease and suggests that enhancing apelin action can be therapeutic for cardiovascular diseases.
Methods
Methods are available in the online-only Data Supplement.
Experimental Animals
Male apelin (APLN)-deficient (APLN −/y ) and littermate WT (APLN +/y ) mice were generated and bred in a C57BL/6 background as previously described. 18 The 10-week aged male WT, APLN −/y , and ApoEKO mice were randomized to receive either Ang II (1.5 mg kg ) or saline with an osmotic minipump for 4 weeks as previously described. 5, 23, 24 In a separate experiment, the Ang II-infused WT or ApoEKO mice were treated daily with placebo or 100 μg/kg pyr1-apelin-13 (Tocris Bioscience; intraperitoneal injection) for 4 weeks. All experiments were approved and performed in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health, Canadian Council on Animal Care, Animal Research Ethics Committee at Shanghai Jiao Tong University School of Medicine, and the University of Alberta.
Cultured Neonatal Cardiomyocytes and Cardiofibroblasts
Primary cardiomyocytes and cardiofibroblasts were cultured from hearts of 1-to 2-day-old neonatal Sprague-Dawley rats as previously described 25, 26 and pretreated with Ang II in the absence and presence of pyr1-apelin-13, PI3K (phosphoinositide 3-kinase) inhibitor LY294002, Akt inhibitor MK2206, Akt agonist SC-79, and endothelial nitric oxide synthase (eNOS) agonist histamine dihydrochloride.
Statistical Analysis
Statistical analyses were performed using the SPSS Statistics 19 software, and a value of P <0.05 was considered statistically significant. Student t test or 1-way ANOVA, followed by multiple-comparison Student Neuman-Keuls testing, was performed to compare the data between 2 or among experimental groups, respectively.
Results

Heart Disease in Aged Apelin-Deficient Hearts With Downregulation of Angiotensin-Converting Enzyme 2
We showed that aging is associated with reduced myocardial apelin levels ( Figure 1A ; Figure S1 in the online-only Data Supplement) and as such we determined the effects of apelin deficiency on aging-induced heart disease. There were no differences in invasive BP between 1-year aged WT and APLN −/y mice ( Figure S2 in the online-only Data Supplement). Compared with aged WT mice, aged APLN −/y mice developed increased myocardial hypertrophy and fibrosis with reduced myocardial microvascular density ( Figure 1B ; Figure S3 in the online-only Data Supplement). These cellular and morphological changes were associated with systolic and diastolic dysfunction as determined by both transthoracic echocardiography and invasive pressure-volume loop analysis ( Figure 1C and 1D). Angiotensin-converting enzyme 2 (ACE2), the major negative regulator of the renin-angiotensin system, has been identified as key target of apelin peptides. 5, 7, 23, 24, 27 Immunofluorescence staining and Western blot analysis revealed downregulation of ACE2 levels in 1-year-old APLN −/y hearts ( Figure 1E ) associated with increased superoxide production and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity ( Figure 1F) . These results clearly demonstrate that loss of apelin results in age-dependent heart disease in association with reduced ACE2 levels.
Loss of Apelin Exacerbates Ang II-Mediated Cardiac Hypertrophy and Dysfunction
We next examined the response of apelin deficiency to Ang II-mediated heart disease. Gross histology and echocardiographical data demonstrated normal morphology and cardiac function between young WT and APLN −/y mice ( Figure 2 ). Importantly, loss of apelin resulted in greater myocardial hypertrophy and remodeling with reduced capillary density in Ang II-treated APLN −/y mice (Figure 2A through 2C). Consistent with the exacerbation of pathological remodeling, Ang II-induced cardiac dysfunction was greater in APLN −/y mice on the basis of decreased left ventricular fractional shortening, ejection fraction, and E/Aʹ ratio coupled with increased isovolumic relaxation time (Figure 2E and 2F; Figure S4 in the online-only Data Supplement). We evaluated the regulatory effects of apelin deficiency on Ang II-induced heart disease and the relevant molecular signaling pathways. Loss of apelin potentiated Ang II-induced perivascular and interstitial myocardial fibrosis ( Figure 3A and 3B) and transcriptional activation of profibrotic mediators ( Figure S5A through S5C in the online-only Data Supplement) resulting in greater accumulation of collagen I and collagen III ( Figure S5D through S5F in the online-only Data Supplement) in APLN −/y hearts. Expression of pathological hypertrophy-associated genes was also increased in Ang II-treated apelin-deficient hearts ( Figure 3C ). These changes were associated with greater elevation in myocardial superoxide levels and NADPH oxidase activity ( Figure 2D ).
Immunofluorescence staining and Western blot analysis showed that apelin deficiency potentiated Ang II-mediated loss of ACE2 (Figure 3D , and p-ERK1/2 (p-extracellular regulated protein kinases 1/2) in WT hearts, whereas increased phosphorylated levels of p38-mitogen-activated protein kinase in APLN −/y hearts without changing signal transducer and activator transcription 3 levels ( Figure 3E ). Loss of apelin also increased levels of p-JAK2 (p-janus kinase 2) and osteopontin and abolished Ang II-mediated increased phosphorylation of p-eNOS ( Figure 3E ). Collectively, these results showed that loss of apelin facilitates Ang II-mediated injury pathways leading to greater pathological hypertrophy and myocardial fibrosis and dysfunction.
Treatment With Pyr1-Apelin-13 Prevented Ang II-Mediated Hypertension and Myocardial Hypertrophy and Dysfunction
We next examined the protective action of pyr1-apelin-13 in Ang II-induced pathological remodeling and cardiac dysfunction in WT and atherosclerosis-prone ApoEKO mice. 4, 16, 23, 24 In ApoEKO mice, myocardial hypertrophy was increased based on morphological characterization ( Figure 4A through 4C) and myocardial cross-sectional area with equivalent pressor response ( Figure 4C ) compared with WT mice in response to Ang II. These changes resulted in impaired heart function in the Ang II-infused ApoEKO mice characterized by ventricular dilation and reduced systolic function ( Figure 4D ; Figure S7 in the online-only Data Supplement). There were no significant changes in systolic BP levels between the Ang II-infused WT and ApoEKO mice ( Figure 4C ). Importantly, pyr1-apelin-13 treatment reversed Ang II-mediated hypertension and pathological hypertrophy in both WT and ApoEKO mice ( Figure 4A through 4C) and the deterioration in systolic function in ApoEKO mice ( Figure 4D ; Figure S7 in the online-only Data Supplement). Ang II also increased myocardial mRNA expression of disease markers atrial natriuretic factor, brain natriuretic showing reduced ACE2 levels, increased superoxide levels and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity in aged APLN −/y hearts. n=8 for each group except for A and F where n=4. *P<0.01 compared with WT group; # P<0.01 compared with APLN −/y 1-year group. APLN indicates apelin; A.U., arbitrary units; DAPI, 4ʹ,6ʹ-diamidino-2-phenylindole; EDV, end-diastolic velocity; Ees, end-systolic elastance; EF, ejection fraction; ESV, end-systolic volume; HW, heart weight; LV, left ventricle; LVEDP, LV end-diastolic pressure; PRSW, preload recruitable stroke work; SOD, polyethylene glycol-superoxide dismutase; and TL, tibia length. December 2017 peptide, and β-myosin heavy chain ( Figure 4E ), in association with increased superoxide levels and NADPH oxidase activity ( Figure 4F ) which were prevented by pyr1-apelin-13 treatment in ApoEKO mice. Our results revealed that pyr1-apelin-13 rescued Ang II-mediated hypertension, pathological hypertrophy, oxidative stress, and cardiac dysfunction.
Pyr1-apelin-13 Treatment Prevented Ang IIMediated Pathological Effects With Normalization of ACE2 Levels
We further evaluated effects of pyr1-apelin-13 on Ang II-mediated injury pathways. Ang II-induced myocardial apoptosis ( Figure 5A ) and fibrosis ( Figure 5B) and altered mice. C, Immunofluorescence staining for wheat germ agglutinin (WGA; green) and CD31 (red) illustrating greater hypertrophy of individual cardiomyocytes of the Ang II-infused APLN −/y hearts with reduced myocardial capillary density. D, Dihydroethidium (DHE) staining with quantification and chemiluminescence lucigenin assay revealed that loss of apelin potentiated Ang II-induced increases in myocardial superoxide levels and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity. E and F, Echocardiography showed that the Ang II-infused APLN −/y mice developed greater hypertrophy, impaired heart function. n=8 for each group except for C and D where n=5. *P<0.01 compared with corresponding placebo-treated group; # P<0.05 compared with WT+Ang II group; ϕ P<0.01 compared with WT+PLC group. APLN indicates apelin; A.U., arbitrary units; DPI, diphenyleneiodonium; EF, ejection fraction; FS, fractional shortening; LV, left ventricle; LVIDd, LV diastolic internal diameter; LVPWd, LV posterior wall thickness at end diastole; PLC, placebo; and WT, wild type. myocardial ultrastructure characterized by disruption or dissolution of myocardial myofilaments, vacuolar degeneration, and swollen mitochondria ( Figure S8 in the online-only Data Supplement) were aggravated in the ApoEKO mice which were prevented by pyr1-apelin-13. These cellular changes were concordant with alterations in collagen volume fraction ( Figure 5C ), mRNA expression of TGF-β1 (transforming growth factor-β1), procollagen Iα1 and procollagen IIIα1 ( Figure 5D ) and protein levels of collagen I and collagen III ( Figure S9 in the online-only Data Supplement), osteopontin, and phosphorylated levels of p-Smad2 ( Figure 5E and 5F). Although Ang II infusion decreased myocardial ACE2 protein, phosphorylated levels of p-Akt Thr 308 , p-Akt Ser
473
, and p-ERK1/2 in WT hearts, there was a greater decrease in ApoEKO hearts coupled with loss of phosphorylated p-eNOS and decreased Bcl2/Bax ratio ( Figure 5F ). Importantly, administration of pyr1-apelin-13 remarkably attenuated Ang II-mediated pathological effects in ApoE-null hearts associated with increased levels of ACE2 and Bcl2 and enhanced phosphorylated levels of p-Akt, p-ERK1/2, and p-eNOS ( Figure 5 ). Our data provide definitive evidence for a protective role of pyr1-apelin-13 in Ang II-mediated myocardial injury and pathological remodeling by normalizing ACE2 levels and activating the Akt-ERK-eNOS signaling pathway.
Pyr1-apelin-13 Is a Negative Regulator of Oxidative Stress, Cellular Proliferation, Migration, and Apoptosis in Cultured Neonatal Cardiomyocytes and Cardiofibroblasts
We further evaluated effects of pyr1-apelin-13 independent of BP-lowering effects. We confirmed the rescue of the Ang II-mediated decreases in ACE2 levels by pyr1-apelin-13 (100 Figure 6A ). To evaluate a more direct effect of pyr1-apelin-13 on Ang II signaling, we also examined the impact of pyr1-apelin-13 on Ang II-mediated actions in cultured cardiomyocytes and cardiofibroblasts. Dihydroethidium fluorescence images showed a marked increase in superoxide production in response to Ang II (100 nmol/L) in neonatal cardiomyocytes and cardiofibroblasts which was blocked by pyr1-apelin-13 (100 nmol/L), Akt agonist SC-79 (10 μmol/L), eNOS agonist histamine dihydrochloride (10 μmol/L), and reactive oxygen species inhibitor N-acetyl-l-cysteine (10 mmol/L), respectively ( Figure 6B ). Expression analysis showed that Ang II-induced . Treatment using pyr1-apelin-13 rescues angiotensin (Ang) II-mediated myocardial hypertrophy, oxidative stress, and impaired heart function in apolipoprotein E (ApoE) knockout (KO) mice. A and B, Gross histology (A) and immunofluorescence wheat germ agglutinin (WGA) staining (B) revealed increased myocardial hypertrophy in Ang II-infused ApoEKO mice that is rescued by pyr1-apelin-13 treatment. C, Cardiomyocyte cross-sectional area, heart weight (HW), HW/body weight (BW) ratio, and systolic blood pressure (BP) levels in mice exhibiting rescue of the Ang II-mediated pathological hypertrophy and pressor response in the ApoEKO hearts by pyr1-apelin-13 treatment. D and E, Echocardiography (D) and real-time PCR analyses (E) showing greater cardiac dysfunction and pathological remodeling in Ang II-treated ApoEKO hearts based on left ventricular posterior wall thickness (LVPWT), LV fractional shortening (FS), LV ejection fraction (EF) and expression of ANF (atrial natriuretic factor), BNP (brain natriuretic peptide), and β-MHC (β-myosin heavy chain), that were prevented by pyr1-apelin-13. F, Dihydroethidium (DHE) staining and chemiluminescence lucigenin assay showing rescue of the Ang II-mediated increases in superoxide production and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity in ApoEKO hearts by pyr1-apelin-13. n=6 for each group except for F where n=4. , and p-eNOS in cardiofibroblasts in response to Ang II was partially prevented by pyr1-apelin-13, and Akt and eNOS agonist stimulation ( Figure 6E) . Moreover, the in vitro wound-healing assay ( Figure 6C ; Figure S11 in the online-only Data Supplement) and flow cytometric analysis ( Figure 6D ) demonstrated increased proliferation, migration, and apoptosis in cultured cardiofibroblasts pretreated with Ang II (100 nmol/L) and suppressed by pyr1-apelin-13, Akt, and eNOS agonists while being augmented by the PI3K inhibitor LY294002. Notably, cotreatment with the Akt inhibitor MK2206 significantly blocked the beneficial effects of pyr1-apelin-13 against Ang II-mediated oxidative stress, cellular proliferation, and proapoptotic actions in neonatal rat cardiofibroblasts. These in vitro results prove that pyr1-apelin-13 can mediate direct effects on neonatal cardiomyocytes and cardiofibroblasts which are mediated in part by activation of the Akt-eNOS phosphorylation signaling. F) analyses of the mRNA of TGF-β1 (transforming growth factor-β1), procollagen type I α1 and III α1, and levels of collagen I, collagen III, osteopontin, p-Smad2, angiotensin-converting enzyme 2 (ACE2), p-Akt 308, p-Akt 473, p-ERK1/2, p-eNOS, Bcl2, and Bax showing a therapeutic response to pyr1-apelin-13. n=4 for each group except for D where n=6. 
P<0
.01 compared with other groups. APLN indicates apelin; A.U., arbitrary units; DAPI, 4ʹ,6ʹ-diamidino-2-phenylindole; ERK1/2, extracellular regulated protein kinases 1/2; eNOS, endothelial nitric oxide synthase; and R.E., relative expression.
Discussion
The apelin/apelin receptor system and the renin-angiotensin system are widely distributed in the cardiovascular system and closely involved in the pathogenesis of hypertension, heart disease, and atherosclerosis. 6, 7, 12, 20, 27 Both ace2 and apelin genes are located on the X chromosome, and both systems are beneficial in the cardiovascular system. Genetic and pharmacological inhibition of ACE2 elevates plasma levels of pyr1-apelin-13 and apelin-17 and enhances their vasodepressor action. 10, 28 ACE2 deficiency leads to hypertension and impaired heart function, while recombinant ACE2 is protective against heart and vascular diseases. 5, 7, 23, 29 Serum ACE2 activity is higher in patients with hypertension or heart failure compared with healthy individuals, whereas plasma apelin levels are suppressed in patients with heart disease. 22, 28, 30 Apelin and ACE2 pathways represent candidate therapeutic targets for treating hypertension, atherosclerosis, and heart failure in preclinical models and patients.. 5, 8, 15, 27, 28 In this study, we demonstrated that aging was associated with reduced myocardial apelin levels in 1-year-old WT mice, and genetic deletion of apelin reduced ACE2 levels in 1-year aged APLN −/y mice. Deletion of apelin did not affect BP which is consistent with a previous study in aged apelin-deficient mice. 27 Our current findings demonstrate a model of cross-talk between apelin and Ang II signaling in controlling myocardial remodeling, fibrosis, and dysfunction in part by the control of ACE2. Moreover, Ang II infusion resulted in enhancement of myocardial hypertrophy, fibrosis, and collagen deposition in WT hearts and greater elevations in both young APLN −/y hearts and ApoEKO hearts. Loss of apelin resulted in increased myocardial reactive oxygen species generation in aged APLN −/y mice and in response to Ang II which was likely driven by downregulation of the ACE2 system, a central negative regulator of Ang II actions. 5, 7, 23 These changes were linked to exacerbation of cardiac dysfunction and greater increases in myocardial hypertrophy and fibrosis in the Ang II-treated ApoEKO hearts. Consistent with the well-known role of apelin in angiogenesis, 13, 18 loss of apelin also compromised the adaptive myocardial angiogenic response. Importantly, pyr1-apelin-13 was able to rescue Ang II-mediated hypertension, cardiac hypertrophy, fibrosis, and dysfunction in the ApoEKO mice with elevated ACE2 levels, implicating that pyr1-apelin-13-mediated upregulation of ACE2 is a key mechanism to inhibit the Ang II-mediated pathological actions. 16, 27 In addition, reduction in ACE2 levels coupled with the increase in osteopontin levels was likely partially responsible for the Ang II-induced pathological hypertrophy and fibrosis in ApoEKO hearts. 5, 31, 32 Pyr1-apelin-13 treatment antagonizes Ang IIinduced atherosclerosis and aneurysm in ApoEKO mice by increasing nitric oxide production and suppressing cardiovascular remodeling independent of BP-lowering effects. 16 In WT mice, Ang II infusion was associated with molecular and cellular changes consistent with heart disease with preserved ejection fraction which were prevented by pyr1-apelin-13. Ang II infusion promoted phosphorylated eNOS levels in WT hearts but suppressed in ApoEKO hearts. These changes were accompanied by decreased phosphorylated levels of p-Akt at both Ser 473 and Thr
308
, p-ERK1/2, and p-eNOS Ser 1177 in Ang II-treated ApoEKO hearts. The function of Ang II is complex and diverse from different concentrations and different animal models because of complexity of action and balance of its relevant enzymes ACE2/ACE. In our previous study, we demonstrated that ACE2 can cleave both Ang II and pyr1-apelin-13, and the hypotensive action of pyr1-apelin-13 was potentiated in ACE2-mutant mice, with a corresponding greater elevation in plasma apelin levels. 10 In previous study, Ang II decreased phosphorylated levels of p-Akt Ser 473 and p-eNOS Ser 1177 and increased reactive oxygen species generation. 33 The Akt/ERK1/2 and eNOS phosphorylation signaling pathways play critical roles in cardioprotection against cellular apoptosis, myocardial injury, and abnormal contractility.. 12, 34 In this study, pyr1-apelin-13 largely attenuated the Ang II-mediated hypertension, apoptosis, hypertrophy, fibrosis, and structural injury in the ApoEKO hearts by phosphorylating and activating the Akt-ERK-eNOS signaling pathway. In our in vitro study using neonatal cardiomyocytes and cardiofibroblasts, exposure of the cells to Ang II decreased phosphorylated levels of p-Akt Ser 473 , p-Akt Thr 308 , and p-eNOS Ser 1177 and increased reactive oxygen species generation, which were rescued by pyr1-apelin-13, Akt, and eNOS agonist stimulation. Notably, Akt inhibition blocked the beneficial effects of pyr1-apelin-13 against Ang II-mediated oxidative stress, cellular proliferation, and proapoptotic actions in neonatal cardiofibroblasts. Our data are consistent with the observation that pyr1-apelin-13 improved oxidative stress, cardiac dysfunction, and injury via activation of the Akt/ERK1/2 and eNOS phosphorylation pathways. The therapeutic action of pyr1-apelin-13 is likely mediated by a combination of antihypertensive and direct protective effects on cardiofibroblasts and cardiomyocytes. Collectively, our results delineated a critical role of pyr1-apelin-13 in the regulation of Ang II-mediated myocardial remodeling, fibrosis, and dysfunction ( Figure 6F ). The interaction between pyr1-apelin-13 peptide and the renin-angiotensin system is also consistent with the protective effects of apelin seen in murine models of pressure overload-induced heart disease. 27, 35 The use of stable apelin analogues that are resistant to degradation by endogenous proteases represents a particularly attractive therapeutic strategy.
36,37
Perspectives
Apelin peptides, as important pharmacological targets, mediate crucial physiological effects in the heart and vasculature, whereas blockade of the Ang II signaling improve heart function and reduce hypertension and cardiovascular events in patients. We showed that loss of apelin leads to reduction of ACE2 and increased oxidative stress, myocardial fibrosis, and dysfunction in response to Ang II. Conversely, pyr1-apelin-13 peptide negatively regulates the Ang II-mediated cardiac remodeling, fibrosis, and injury. The improvement of cardiac dysfunction and injury and hypotensive effects of pyr1-apelin-13 in ApoEKO mice are likely driven by enhancement of ACE2 levels and activation of protective signaling transduction pathways including phosphorylation of Akt/ERK1/2 and eNOS. We demonstrated that the apelin pathway is protective against Ang II-mediated heart disease. Thus, targeting the apelin/apelin receptor pathway represents a novel therapeutic approach against cardiovascular disease.
